drugset / Trial / NCT02360631
Advancing Tobacco Use Treatment for African American Smokers
Phase 4
Completed
500 enrolled
Lisa Sanderson Cox, PhD
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to examine whether or not providing Chantix (varenicline) will help African American smokers quit smoking.
Timeline
- Start
- 2015-07-29
- Primary completion
- 2018-07-12
- Completion
- 2018-07-12
Outcome
Met primary endpoint
paper varenicline were significantly more likely than those receiving placebo to be abstinent at week 26 PMID 35699705 ↗
paper abstinent at week 26 (15.7% vs 6.5%; difference, 9.2% [95% CI, 3.8%-14.5%]; odds ratio [OR], 2.7 [95% CI, 1.4-5.1]; P = .002). PMID 35699705 ↗
Publications
- Lambart L, Nollen NL, Mayo MS, Funk O, Leavens E, Cruvinel E, Brown A, Ahluwalia JS, Sanderson Cox L. The impact of blunt use on smoking abstinence among Black adults: Secondary analysis from randomized controlled smoking cessation clinical trial. Addict Behav. 2024 Jan;148:107877. doi: 10.1016/j.addbeh.2023.107877. Epub 2023 Oct 4.
- Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
- Cox LS, Nollen NL, Mayo MS, Faseru B, Greiner A, Ellerbeck EF, Krebill R, Tyndale RF, Benowitz NL, Ahluwalia JS. Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial. JAMA. 2022 Jun 14;327(22):2201-2209. doi: 10.1001/jama.2022.8274.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varenicline | Small molecule | 1 mg | Oral |
Indications
No indication recorded.